Stepan Reports Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
Stepan (NYSE: SCL) reported Q4 2025 net income of $5.0M (up 49% YoY) and adjusted EBITDA of $33.8M (down 3% YoY). Full-year 2025 results include net income of $46.9M (down 7%), net sales of $2.332B (up 7%), EBITDA of $208.0M (up 11%) and adjusted EBITDA of $198.9M (up 6%).
The company announced Project Catalyst targeting approximately $100M pre-tax savings over two years and expects 2026 adjusted EBITDA growth and positive free cash flow.
Positive
- Full-year EBITDA +11% to $208.0M
- Full-year adjusted EBITDA +6% to $198.9M
- Net sales +7% to $2.332B
- Announced Project Catalyst targeting $100M pre-tax savings over two years
- Polymer volume +11% in Q4
- Reduced Net Debt by $31.7M and Leverage Ratio to 2.5
Negative
- Full-year reported net income down 7% to $46.9M
- Full-year adjusted net income down 17% to $41.7M
- Surfactants operating income Q4 down 42% versus prior year
- Q4 consolidated adjusted EBITDA down 3% to $33.8M
News Market Reaction – SCL
On the day this news was published, SCL declined 20.38%, reflecting a significant negative market reaction. Argus tracked a trough of -13.5% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $352M from the company's valuation, bringing the market cap to $1.38B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only one peer (LWLG) up 1.45% without news. Listed specialty-chemical peers (ECVT, ODC, KRO, MATV, KOP) show mixed single‑stock moves, with no clear, coordinated sector trend indicated.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Q3 2025 earnings | Neutral | -0.4% | Net income down but adjusted EBITDA and net sales grew modestly. |
| Jul 30 | Q2 2025 earnings | Positive | -9.7% | Strong gains in net income, adjusted net income, and Adjusted EBITDA. |
| Apr 29 | Q1 2025 earnings | Positive | +7.1% | Robust net income, volume growth, and double-digit adjusted EBITDA increase. |
| Feb 19 | Q4 2024 earnings | Neutral | +0.1% | Return to profitability but sharply lower adjusted net income year over year. |
| Oct 30 | Q3 2024 earnings | Positive | +2.0% | Strong growth in net income, adjusted net income, and EBITDA metrics. |
Earnings releases often show operational progress (EBITDA growth, volume gains) but market reactions have generally been modest, with one notable negative divergence on strong Q2 2025 results.
Across the last five earnings reports (Q3 2024 through Q3 2025), Stepan has repeatedly highlighted adjusted EBITDA growth, evolving product mix, and volume gains in key segments, while also absorbing higher taxes and start-up costs at the Pasadena, Texas facility. 2025 updates added asset divestitures in the Philippines and footprint optimization themes. Today’s Q4 and full-year 2025 results continue those narratives with higher EBITDA, modest volume growth, and ongoing cost and portfolio actions framing the outlook.
Historical Comparison
Over the last five earnings releases, SCL’s average 24-hour move was -0.17%, indicating generally muted price reactions to mixed trends in net income and adjusted EBITDA.
Earnings since late 2024 show a shift from Pasadena start-up drag toward steadier adjusted EBITDA growth, while 2025 layered in footprint optimization via Philippine and Lake Providence asset sales and modest global volume gains.
Market Pulse Summary
The stock dropped -20.4% in the session following this news. A negative reaction despite EBITDA and sales growth would fit past instances where strong operational metrics coincided with cautious sentiment, such as Q2 2025. The decline could reflect focus on weaker adjusted net income, higher tax rates, and restructuring risks tied to Project Catalyst. With Q4 2025 adjusted EBITDA at $33.8M and ongoing footprint optimization, execution on cost savings and volume stability would remain key considerations.
Key Terms
ebitda financial
adjusted ebitda financial
free cash flow financial
non-gaap financial
AI-generated analysis. Not financial advice.
Fourth Quarter 2025 Highlights
- Reported net income was
, up$5.0 million 49% versus the prior year. Adjusted net income(1) was a loss, down$0.5 million 119% versus the prior year, largely due to higher interest expense, resulting from lower capitalized interest income recognition due to thePasadena, TX site start-up, a less favorable effective tax rate and lower Surfactant earnings. - EBITDA(2) was
, up$43.3 million 21% versus the prior year. Adjusted EBITDA(2) was , down$33.8 million 3% year-over-year. - Global sales volume was down
3% year-over-year. Global sales volume, excluding the impact ofthe Philippines asset divestiture, was flat year-over-year. - Cash from Operations was
during the quarter. Free cash flow(3) for the quarter was$60.0 million , driven by a reduction in working capital.$25.4 million - Pre-tax earnings include
of goodwill impairment expense related to the Company's Mexican reporting unit and$6.2 million of gains related to the previously announced$15.9 million Philippines andLake Providence, LA asset divestitures.
Full Year 2025 Highlights
- Reported net income was
, down$46.9 million 7% versus the prior year. Adjusted net income(1) was , down$41.7 million 17% versus the prior year. - EBITDA(2) was
and Adjusted EBITDA(2) was$208.0 million , up$198.9 million 11% and6% , respectively, year-over-year. - Global sales volume was up
1% year-over-year. Global sales volume, excluding the impact ofthe Philippines asset divestiture, was up2% year-over-year.
"2025 was a transformational year for Stepan as we divested two plant sites and completed preliminary work that has positioned us to further optimize our footprint and asset base in 2026. Despite many challenges in 2025, we delivered growth in several of our core businesses, advanced several strategic initiatives and have an operational plan in place to accelerate profitable growth moving forward. Full year adjusted EBITDA grew
Financial Summary
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
($ in thousands, except per share data) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
Net Sales | $ | 553,886 | $ | 525,609 | 5 | % | $ | 2,332,114 | $ | 2,180,274 | 7 | % | ||||||||||||
Operating Income | $ | 10,502 | $ | 7,695 | 36 | % | $ | 78,549 | $ | 70,480 | 11 | % | ||||||||||||
Net Income | $ | 5,004 | $ | 3,350 | 49 | % | $ | 46,895 | $ | 50,370 | (7) | % | ||||||||||||
Earnings per Diluted Share | $ | 0.22 | $ | 0.15 | 47 | % | $ | 2.05 | $ | 2.20 | (7) | % | ||||||||||||
Adjusted Net Income * | $ | (531) | $ | 2,757 | (119) | % | $ | 41,680 | $ | 50,470 | (17) | % | ||||||||||||
Adjusted Earnings per | $ | (0.02) | $ | 0.12 | (117) | % | $ | 1.82 | $ | 2.20 | (17) | % | ||||||||||||
* See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
Percentage Change in Net Sales
Net sales in the fourth quarter of 2025 increased
Three Months Ended | Twelve Months Ended | |||||||
Volume | (3) | % | 1 | % | ||||
Selling Price & Mix | 5 | % | 6 | % | ||||
Foreign Translation | 3 | % | (—) | % | ||||
Total | 5 | % | 7 | % | ||||
Segment Results
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
($ in thousands) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
Net Sales | ||||||||||||||||||||||||
Surfactants | $ | 401,832 | $ | 378,776 | 6 | % | $ | 1,665,983 | $ | 1,532,115 | 9 | % | ||||||||||||
Polymers | $ | 131,682 | $ | 129,844 | 1 | % | $ | 584,477 | $ | 584,905 | (0) | % | ||||||||||||
Specialty Products | $ | 20,372 | $ | 16,989 | 20 | % | $ | 81,654 | $ | 63,254 | 29 | % | ||||||||||||
Total Net Sales | $ | 553,886 | $ | 525,609 | 5 | % | $ | 2,332,114 | $ | 2,180,274 | 7 | % | ||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
($ in thousands, all amounts pre-tax) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
Operating Income | ||||||||||||||||||||||||
Surfactants | $ | 9,343 | $ | 16,173 | (42) | % | $ | 67,358 | $ | 85,618 | (21) | % | ||||||||||||
Polymers | $ | 3,984 | $ | 3,396 | 17 | % | $ | 43,265 | $ | 40,623 | 7 | % | ||||||||||||
Specialty Products | $ | 5,240 | $ | 5,594 | (6) | % | $ | 25,640 | $ | 20,908 | 23 | % | ||||||||||||
Total Segment | $ | 18,567 | $ | 25,163 | (26) | % | $ | 136,263 | $ | 147,149 | (7) | % | ||||||||||||
Corporate Expenses | $ | (8,065) | $ | (17,468) | (54) | % | $ | (57,714) | $ | (76,669) | (25) | % | ||||||||||||
Consolidated | $ | 10,502 | $ | 7,695 | 36 | % | $ | 78,549 | $ | 70,480 | 11 | % | ||||||||||||
Three Months Ended | Year Ended | |||||||||||||||||||||||
($ in millions) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
EBITDA | $ | 43.3 | $ | 35.8 | 21 | % | $ | 208.0 | $ | 186.9 | 11 | % | ||||||||||||
Adjusted EBITDA | ||||||||||||||||||||||||
Surfactants | $ | 32.1 | $ | 34.7 | (7) | % | $ | 153.0 | $ | 157.6 | (3) | % | ||||||||||||
Polymers | $ | 12.4 | $ | 11.4 | 9 | % | $ | 76.4 | $ | 73.0 | 5 | % | ||||||||||||
Specialty Products | $ | 6.7 | $ | 7.1 | (6) | % | $ | 31.5 | $ | 26.9 | 17 | % | ||||||||||||
Unallocated Corporate | $ | (17.4) | $ | (18.2) | (4) | % | $ | (62.0) | $ | (70.5) | (12) | % | ||||||||||||
Consolidated Adjusted EBITDA | $ | 33.8 | $ | 35.0 | (3) | % | $ | 198.9 | $ | 187.0 | 6 | % | ||||||||||||
Consolidated adjusted EBITDA(2) decreased
- Surfactant net sales were
for the quarter, a$401.8 million 6% increase versus the prior year. Selling prices were up10% primarily due to pass through of higher raw material costs, improved product and customer mix, along with pricing actions. Sales volume declined7% year-over-year primarily due to lower demand within the commodity Laundry & Cleaning end markets, lower demand from our distribution partners and lower volume inthe Philippines due to the asset divestiture. Excluding the impact ofthe Philippines , organic volume declined3% . These declines were partially offset by double digit growth within the Industrial Cleaning end markets and year-over-year growth within the Agricultural and Oilfield end markets. Foreign currency translation positively impacted net sales by3% . Surfactant adjusted EBITDA(2) for the quarter decreased , or$2.6 million 7% , versus the prior year. This decrease was primarily due to the7% decrease in sales volume. - Polymer net sales were
for the quarter, a$131.7 million 1% increase versus the prior year. Selling prices decreased12% , primarily due to the pass-through of lower raw material costs and competitive pressures. Sales volume increased11% in the quarter. North American Rigid and commodity Phthalic Anhydride sales volume was up double digits year-over-year. Foreign currency translation positively impacted net sales by2% during the quarter. Polymer adjusted EBITDA(2) increased , or$1.0 million 9% , versus the prior year primarily due to the11% increase in sales volume. - Specialty Products net sales were
for the quarter, a$20.4 million 20% increase versus the prior year, primarily due to higher sales volume. Specialty Products adjusted EBITDA(2) decreased , or$0.4 million 6% . The decrease in adjusted EBITDA(2) was primarily due to lower margins resulting from order timing fluctuations within the pharmaceutical business.
Income Taxes
The Company's effective tax rate was
Outlook
"As we look forward to 2026, we remain focused on delivering superior shareholder returns with a balanced approach between top line growth and productivity cost out efforts. Today we announced Project Catalyst, which is a comprehensive plan designed to further optimize our asset base and create a more productive and agile organization to enable growth. Project Catalyst is expected to deliver approximately
Notes
(1) Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
(2) EBITDA and adjusted EBITDA are non-GAAP measures. See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA. |
(3) Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures. Cash generated from operations was |
Conference Call
Stepan Company will host a conference call to discuss its third quarter results at 9:00 a.m. ET (8:00 a.m. CT) on February 23, 2026. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.
Corporate Profile
Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.
Headquartered in
The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com
More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com.
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.
There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, changes in global trade policies, including tariffs; legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants. In addition to the risks described in the Company's periodic reports, the restructuring actions described herein may involve risks related to the execution of facility closures and asset decommissioning, potential operational disruptions, impacts on employees and local communities, environmental compliance, and the realization of anticipated cost savings and efficiencies.
These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.
* * * * *
Tables follow
Table I
STEPAN COMPANY For the Three and Twelve Months Ended December 31, 2025 and 2024 (Unaudited – in 000's, except per share data) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net Sales | $ | 553,886 | $ | 525,609 | $ | 2,332,114 | $ | 2,180,274 | ||||||||
Cost of Sales | 502,369 | 468,913 | 2,062,226 | 1,908,060 | ||||||||||||
Gross Profit | 51,517 | 56,696 | 269,888 | 272,214 | ||||||||||||
Operating Expenses: | ||||||||||||||||
Selling | 10,703 | 11,018 | 48,767 | 45,628 | ||||||||||||
Administrative | 23,710 | 24,764 | 90,789 | 98,277 | ||||||||||||
Research, Development and Technical Services | 15,703 | 13,793 | 59,278 | 55,674 | ||||||||||||
Deferred Compensation Expense | 549 | (574) | 2,155 | 2,155 | ||||||||||||
50,665 | 49,001 | 200,989 | 201,734 | |||||||||||||
Goodwill Impairment | 6,245 | - | 6,245 | - | ||||||||||||
Gain on sale of assets | (15,895) | - | (15,895) | |||||||||||||
Operating Income | 10,502 | 7,695 | 78,549 | 70,480 | ||||||||||||
Other Income (Expense): | ||||||||||||||||
Interest, Net | (5,689) | (4,829) | (22,115) | (14,182) | ||||||||||||
Other, Net | 126 | (410) | 3,470 | 4,141 | ||||||||||||
(5,563) | (5,239) | (18,645) | (10,041) | |||||||||||||
Income Before Provision for Income Taxes | 4,939 | 2,456 | 59,904 | 60,439 | ||||||||||||
Provision for Income Taxes | (65) | (894) | 13,009 | 10,069 | ||||||||||||
Net Income | 5,004 | 3,350 | 46,895 | 50,370 | ||||||||||||
Net Income Per Common Share | ||||||||||||||||
Basic | $ | 0.22 | $ | 0.15 | $ | 2.05 | $ | 2.21 | ||||||||
Diluted | $ | 0.22 | $ | 0.15 | $ | 2.05 | $ | 2.20 | ||||||||
Shares Used to Compute Net Income Per | ||||||||||||||||
Basic | 22,878 | 22,841 | 22,872 | 22,832 | ||||||||||||
Diluted | 22,891 | 22,912 | 22,890 | 22,931 | ||||||||||||
Table II
Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share* | ||||||||||||||||||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||||||||||
($ in thousands, except per share amounts) | 2025 | EPS | 2024 | EPS | 2025 | EPS | 2024 | EPS | ||||||||||||||||||||||||
Net Income Reported | $ | 5,004 | $ | 0.22 | $ | 3,350 | $ | 0.15 | $ | 46,895 | $ | 2.05 | $ | 50,370 | $ | 2.20 | ||||||||||||||||
Deferred Compensation (Income) | $ | 76 | $ | 0.01 | $ | (762) | $ | (0.03) | $ | (473) | $ | (0.02) | $ | (1,805) | $ | (0.08) | ||||||||||||||||
Environmental Remediation | $ | 65 | $ | 0.00 | $ | 169 | $ | - | $ | 934 | $ | 0.04 | $ | 1,905 | $ | 0.08 | ||||||||||||||||
Goodwill Impairment | $ | 6,245 | $ | 0.27 | $ | - | $ | - | $ | 6,245 | $ | 0.27 | $ | - | $ | - | ||||||||||||||||
Gain on Sale of Assets | $ | (11,921) | $ | (0.52) | $ | - | $ | - | $ | (11,921) | $ | (0.52) | $ | - | $ | - | ||||||||||||||||
Adjusted Net Income | $ | (531) | $ | (0.02) | $ | 2,757 | $ | 0.12 | $ | 41,680 | $ | 1.82 | $ | 50,470 | $ | 2.20 | ||||||||||||||||
* All amounts in this table are presented after-tax |
The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition. The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators. Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years. These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies. The Company's Annual Report on Form 10-K for the year ended December 31, 2024 contains additional information regarding the use of non-GAAP financial measures.
Summary of Fourth Quarter 2025 Adjusted Net Income Items
Adjusted net income excludes non-operational deferred compensation income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.
- Deferred Compensation: The fourth quarter of 2025 reported net income includes
of after-tax expense versus$0.1 million of after-tax income in the prior year.$0.8 million - Environmental Remediation: The fourth quarter of 2025 reported net income includes
of after-tax expense versus$0.1 million of after-tax expense in the prior year.$0.2 million - Goodwill Impairment: The fourth quarter of 2025 reported net income includes
of after-tax expense related to a goodwill impairment charge taken for the Company's Mexican reporting unit. There were no impairment charges taken in the prior year.$6.2 million - Gain on Sale of Assets: The fourth quarter of 2025 reported net income includes
of after-tax income related to the previously announced$11.9 million Philippines andLake Providence, LA asset sales.
Table III
Reconciliation of Pre-Tax to After-Tax Adjustments
Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||||||||||
($ in thousands, except per share amounts) | 2025 | EPS | 2024 | EPS | 2025 | EPS | 2024 | EPS | ||||||||||||||||||||||||
Pre-Tax Adjustments | ||||||||||||||||||||||||||||||||
Deferred Compensation (Income) | $ | 101 | $ | (1,016) | $ | (631) | $ | (2,406) | ||||||||||||||||||||||||
Environmental Remediation Expense | $ | 87 | $ | 225 | $ | 1,245 | $ | 2,540 | ||||||||||||||||||||||||
Goodwill Impairment | $ | 6,245 | $ | - | $ | 6,245 | $ | - | ||||||||||||||||||||||||
Gain on Sale of Assets | $ | (15,895) | $ | - | $ | (15,895) | $ | - | ||||||||||||||||||||||||
Total Pre-Tax Adjustments | $ | (9,462) | $ | (791) | $ | (9,036) | $ | 134 | ||||||||||||||||||||||||
Cumulative Tax Effect on Adjustments | $ | 3,927 | $ | 198 | $ | 3,821 | $ | (34) | ||||||||||||||||||||||||
After-Tax Adjustments | $ | (5,535) | $ | (0.24) | $ | (593) | $ | (0.03) | $ | (5,215) | $ | (0.23) | $ | 100 | $ | 0.00 | ||||||||||||||||
Table IV
Deferred Compensation Plans
The full effect of the deferred compensation plans on quarterly pre-tax income was
2025 | 2024 | |||||||||||||||||||||||||||||||
12/31 | 9/30 | 6/30 | 3/31 | 12/31 | 9/30 | 6/30 | 3/31 | |||||||||||||||||||||||||
Stepan Company | $ | 47.36 | $ | 47.70 | $ | 54.58 | $ | 55.04 | $ | 64.70 | $ | 77.25 | $ | 83.96 | $ | 90.04 | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
($ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
Deferred Compensation | ||||||||||||||||
Operating Income (Expense) | $ | (549) | $ | 574 | $ | (2,155) | $ | (2,155) | ||||||||
Other, net – Mutual Fund Gain (Loss) | 448 | 442 | 2,786 | 4,561 | ||||||||||||
Total Pre-Tax | $ | (101) | $ | 1,016 | $ | 631 | $ | 2,406 | ||||||||
Total After-Tax | $ | (76) | $ | 762 | $ | 473 | $ | 1,805 | ||||||||
Effects of Foreign Currency Translation
The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into
($ in millions) | Three Months Ended | Change | Change | Twelve Months Ended | Change | Change | ||||||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||||||||
Net Sales | $ | 553.9 | $ | 525.6 | $ | 28.3 | $ | 16.1 | $ | 2,332.1 | $ | 2,180.3 | $ | 151.8 | $ | 4.6 | ||||||||||||||||
Gross Profit | 51.5 | 56.7 | $ | (5.2) | 1.5 | 269.9 | 272.2 | $ | (2.3) | (0.4) | ||||||||||||||||||||||
Operating Income | 10.5 | 7.7 | $ | 2.8 | 0.7 | 78.5 | 70.5 | $ | 8.0 | (0.8) | ||||||||||||||||||||||
Pretax Income | 4.9 | 2.5 | $ | 2.4 | 0.5 | 59.9 | 60.4 | $ | (0.5) | (1.1) | ||||||||||||||||||||||
Corporate Expenses | ||||||||||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
($ in thousands) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
Total Corporate Expenses | $ | 8,065 | $ | 17,468 | (54) | % | $ | 57,714 | $ | 76,669 | (25) | % | ||||||||||||
Less: | ||||||||||||||||||||||||
Deferred Compensation Expense | $ | 549 | $ | (574) | (196) | % | $ | 2,155 | $ | 2,155 | (—) | % | ||||||||||||
Environmental Remediation | $ | 87 | $ | 225 | (61) | % | $ | 1,245 | $ | 2,540 | (51) | % | ||||||||||||
Goodwill Impairment | $ | 6,245 | $ | - | NM | $ | 6,245 | $ | - | NM | ||||||||||||||
Gain on Sale of Assets | $ | (15,895) | $ | - | NM | $ | (15,895) | $ | - | NM | ||||||||||||||
Adjusted Corporate Expenses | $ | 17,079 | $ | 17,817 | (4) | % | $ | 63,964 | $ | 71,974 | (11) | % | ||||||||||||
Adjusted Corporate expenses decreased
Table V
Stepan Company Consolidated Balance Sheets December 31, 2025 and December 31, 2024 | ||||||||
December 31, 2025 | December 31, 2024 | |||||||
ASSETS | ||||||||
Current Assets | $ | 858,959 | $ | 810,429 | ||||
Property, Plant & Equipment, Net | 1,219,627 | 1,198,454 | ||||||
Other Assets | 279,116 | 295,765 | ||||||
Total Assets | $ | 2,357,702 | $ | 2,304,648 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities | $ | 666,494 | $ | 669,034 | ||||
Deferred Income Taxes | 11,450 | 9,612 | ||||||
Long-term Debt | 340,975 | 332,632 | ||||||
Other Non-current Liabilities | 94,773 | 123,436 | ||||||
Total Stepan Company Stockholders' Equity | 1,244,010 | 1,169,934 | ||||||
Total Liabilities and Stockholders' Equity | $ | 2,357,702 | $ | 2,304,648 | ||||
Selected Balance Sheet Information
The Company's total debt decreased by
($ in millions) | December 31, | September 30, | June 30, | March 31, | December 31, | ||||||||||||||
Net Debt | |||||||||||||||||||
Total Debt | $ | 626.7 | $ | 655.5 | $ | 658.0 | $ | 659.3 | $ | 625.4 | |||||||||
Cash | 132.7 | 118.5 | 88.9 | 107.5 | 99.7 | ||||||||||||||
Net Debt | $ | 494.0 | $ | 537.0 | $ | 569.1 | $ | 551.8 | $ | 525.7 | |||||||||
Equity | 1,244.0 | 1,246.8 | 1,241.7 | 1,200.5 | 1,169.9 | ||||||||||||||
Net Debt + Equity | $ | 1,738.0 | $ | 1,783.8 | $ | 1,810.8 | $ | 1,752.3 | $ | 1,695.6 | |||||||||
Net Debt / (Net Debt + Equity) | 28 | % | 30 | % | 31 | % | 31 | % | 31 | % | |||||||||
The major working capital components were:
($ in millions) | December 31, | September 30, | June 30, | March 31, | December 31, | ||||||||||||||
Net Receivables | $ | 388.0 | $ | 436.1 | $ | 442.2 | $ | 436.5 | $ | 388.0 | |||||||||
Inventories | 298.8 | 324.3 | 329.5 | 309.3 | 288.7 | ||||||||||||||
Accounts Payable | (261.7) | (289.4) | (281.8) | (298.1) | (258.8) | ||||||||||||||
$ | 425.1 | $ | 471.0 | $ | 489.9 | $ | 447.7 | $ | 417.9 | ||||||||||
Table VI
Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA
Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income.
Three Months Ended | ||||||||||||||||||||
($ in millions) | Surfactants | Polymers | Specialty | Unallocated | Consolidated | |||||||||||||||
Operating Income | $ | 9.4 | $ | 4.0 | $ | 5.2 | $ | (8.1) | $ | 10.5 | ||||||||||
Depreciation and Amortization | 22.7 | 8.4 | 1.5 | 0.1 | 32.7 | |||||||||||||||
Other, Net Income | - | - | - | 0.1 | 0.1 | |||||||||||||||
EBITDA | $ | 43.3 | ||||||||||||||||||
Deferred Compensation | - | - | - | 0.1 | 0.1 | |||||||||||||||
Environmental Remediation | - | - | - | 0.1 | 0.1 | |||||||||||||||
Goodwill Impairment | - | - | - | 6.2 | 6.2 | |||||||||||||||
Gain on Sale of Assets | - | - | - | (15.9) | (15.9) | |||||||||||||||
Adjusted EBITDA | $ | 32.1 | $ | 12.4 | $ | 6.7 | $ | (17.4) | $ | 33.8 | ||||||||||
Three Months Ended | ||||||||||||||||||||
($ in millions) | Surfactants | Polymers | Specialty | Unallocated | Consolidated | |||||||||||||||
Operating Income | $ | 16.2 | $ | 3.4 | $ | 5.6 | $ | (17.5) | $ | 7.7 | ||||||||||
Depreciation and Amortization | 18.5 | 8.0 | 1.5 | 0.5 | 28.5 | |||||||||||||||
Other, Net Income | - | - | - | (0.4) | (0.4) | |||||||||||||||
EBITDA | $ | 35.8 | ||||||||||||||||||
Deferred Compensation | - | - | - | (1.0) | (1.0) | |||||||||||||||
Environmental Remediation | - | - | - | 0.2 | 0.2 | |||||||||||||||
Adjusted EBITDA | $ | 34.7 | $ | 11.4 | $ | 7.1 | $ | (18.2) | $ | 35.0 | ||||||||||
Twelve Months Ended | ||||||||||||||||||||
($ in millions) | Surfactants | Polymers | Specialty | Unallocated | Consolidated | |||||||||||||||
Operating Income | $ | 67.4 | $ | 43.3 | $ | 25.6 | $ | (57.8) | $ | 78.5 | ||||||||||
Depreciation and Amortization | 85.6 | 33.1 | 5.9 | 1.4 | 126.0 | |||||||||||||||
Other, Net Income | - | - | - | 3.5 | 3.5 | |||||||||||||||
EBITDA | $ | 208.0 | ||||||||||||||||||
Deferred Compensation | - | - | - | (0.6) | (0.6) | |||||||||||||||
Environmental Remediation | - | - | - | 1.2 | 1.2 | |||||||||||||||
Goodwill Impairment | - | - | - | 6.2 | 6.2 | |||||||||||||||
Gain on Sale of Assets | - | - | - | (15.9) | (15.9) | |||||||||||||||
Adjusted EBITDA | $ | 153.0 | $ | 76.4 | $ | 31.5 | $ | (62.0) | $ | 198.9 | ||||||||||
Twelve Months Ended | ||||||||||||||||||||
($ in millions) | Surfactants | Polymers | Specialty | Unallocated | Consolidated | |||||||||||||||
Operating Income | $ | 85.6 | $ | 40.6 | $ | 20.9 | $ | (76.6) | $ | 70.5 | ||||||||||
Depreciation and Amortization | 72.0 | 32.4 | 6.0 | 1.9 | 112.3 | |||||||||||||||
Other, Net Income | - | - | - | 4.1 | 4.1 | |||||||||||||||
EBITDA | $ | 186.9 | ||||||||||||||||||
Deferred Compensation | - | - | - | (2.4) | (2.4) | |||||||||||||||
Environmental Remediation | - | - | - | 2.5 | 2.5 | |||||||||||||||
Adjusted EBITDA | $ | 157.6 | $ | 73.0 | $ | 26.9 | $ | (70.5) | $ | 187.0 | ||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/stepan-reports-fourth-quarter-and-full-year-2025-results-302694000.html
SOURCE Stepan Company